Opko Health

OPK

Market cap $1.1B

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models  Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models.

MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is approved in Macau, and the companies expect regulatory approvals in China and related territories in 2027.

ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health platform designed to give consumers direct access to high-quality laboratory testing.

OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base.

OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript

Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

OPKO Health (OPK) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.

MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19.